Navigation Links
Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application
Date:6/23/2011

AMSTERDAM, June 24, 2011 /PRNewswire/ --


 

- Dossier Re-Examination Process Initiated

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it has received an opinion on its Marketing Authorisation Application (MAA) for Glybera® (alipogene tiparvovec) as a potential therapy for Lipoprotein Lipase Deficiency ("LPLD"). Following a recent meeting with the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), AMT has been notified that, at this time, Glybera is not approvable.

Subsequent to a review of the CHMP's letter, AMT believes that Glybera can receive a positive opinion subject to generating additional data from existing patients. AMT has therefore decided to ask for a re-examination of the clinical data package.

"From what we know today, despite the disappointment, we believe that there is an indication from the CHMP that Glybera could receive approval and that the current opinion at this time is a reflection of insufficient proof of clinical benefit of Glybera as a result of low patient numbers measured for chylomicron handling for at least 12 months post treatment. The CHMP also indicated that if certain additional data from already treated patients would confirm current results by the end of 2011, an approval may be possible," noted Jörn Aldag, CEO of AMT. "In the dossier, we provided important data showing Glybera is safe and prevents episodes of pancreatitis, the major clinical complication of LPLD. We appreciate the CHMP's responsibility for caution on such an advanced therapy, so we will work diligently to generate more information and, we hope, ensure that Glybera will still reach patients."

Next steps

As part of the MAA, AMT presented data to the CHMP on Glybera showing evidence in reducing the risk of pancreatitis. Also, the company demonstrated a clear signal of patients' ability to b
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011
2. Amsterdam Molecular Therapeutics Reports Promising Data From Cholesterol Lowering Gene Therapy Study
3. PharmacoFore, Inc. Announces Positive Results from a Phase I Clinical Study of Its Hydromorphone Bio-Activated Molecular Delivery™ System, and Upcoming Presentation at the 2011 BIO Business Forum During the Annual BIO International Convention in Was
4. Latest Molecular Diagnostics Technology Aids German Hospital in Management of European E. coli Crisis
5. Data from Clinical Studies of bioTheranostics CancerTYPE ID® and Breast Cancer Index(SM) Molecular Diagnostic Tests Presented at ASCO 2011 Annual Meeting
6. ImaginAb, Inc. Announces Availability of Custom Protein Radiolabeling Services for Molecular Imaging
7. Medco Partners With MolecularMD on Personalized Medicine Program for Chronic Myeloid Leukemia
8. The World Leader in Molecular Breast Imaging to Premiere Largest Detector in the Industry
9. Gen-Probe Files for US Regulatory Clearance of PANTHER™ System, Fully Automated and Integrated Molecular Testing Instrument
10. Latest Clinical Evidence Supports Promising Outlook for Low-Dose Molecular Breast Imaging (MBI)
11. Cepheid Extends Rapid Molecular Diagnostics Leadership with FDA Clearance of Xpert Clostridium difficile/Epi
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014  BioScrip ® , Inc. (NASDAQ: ... , President and Chief Executive Officer, will present at the Bank ... , , , Date: , , , Wednesday, December ... 2:50 p.m. EST , , , , Location: , , ... About BioScrip, Inc. BioScrip, Inc. ...
(Date:11/26/2014)... RADNOR, Pa. , Nov. 26, 2014 ... dedicated to the development of innovative transdermal synthetic cannabinoid ... the Piper Jaffray 26th Annual Healthcare Conference 2014. The ... the New York Palace in New York ... , will present at 4:50 pm on Tuesday, December ...
(Date:11/26/2014)... , Nov. 26, 2014  Aridis Pharmaceuticals, ... produce novel therapies for infectious diseases, announced today ... an internationally recognized key opinion leader in the ... scientific advisory board. Founder and Chief ... "We believe Dr. Opal,s extensive experience investigating bacterial ...
Breaking Medicine Technology:Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3
... A new study by researchers at Harvard ... vitamins, including B6, B12, and folic acid, lower risk ... leading causes of vision loss among older Americans. These ... fatty acids and phytosterols, are also contained in the ...
... and PCPs Vary in Their Prescribing Patterns of Levodopa/Carbidopa ... Decision ResourcesWALTHAM, Mass., March 4 Decision Resources, one ... on pharmaceutical and healthcare issues, finds that second-line patient ... 14.1 percent to 35.2 percent since last year,s report. ...
Cached Medicine Technology:Harvard Study Shows Folic Acid, B Vitamins in Animi-3(R) May Prevent Vision Loss 2Teva's Azilect Use Dramatically Increases in Second-Line Therapy for the Treatment of Parkinson's Disease 2Teva's Azilect Use Dramatically Increases in Second-Line Therapy for the Treatment of Parkinson's Disease 3
(Date:11/27/2014)... (PRWEB) November 28, 2014 This is ... of the global Bronchoscopes industry with a focus on ... the market status of the Bronchoscopes manufacturers and is ... and individuals interested in the industry. , Firstly, the ... its definition, applications and manufacturing technology. Then, the report ...
(Date:11/27/2014)... The American Society for Clinical Pathology (ASCP) ... in honor of World AIDS Day 2014. On Nov. 25, ... cure.” icon and infographic designed to generate public awareness about ... HIV. , ASCP has asked members to replace their Facebook, ... Get Tested. Find a cure.” icon and share the accompanying ...
(Date:11/27/2014)... 27, 2014 According to a recent ... looking to break into the surgical robotics market ... other than the MIS field dominated by Intuitive. These ... U.S. surgical robotics market by 2020. , “The ... Kamran Zamanian, CEO and President of iData. “System sales ...
(Date:11/27/2014)... November 27, 2014 In a ... allot to sleep has lessened, and due to ... the quality of sleep has eroded. According to ... on the job (Reference: http://www.webmd.com/sleep-disorders/features/sleep-deprivation-workplace ). This ... index by an incalculable amount, leading not only ...
(Date:11/27/2014)... PITTSBURGH, PA (PRWEB) November 27, 2014 ... suffer the embarrassing side effects of urinary incontinence," said ... to it and developed this specialized accessory to prevent ... developed the Incontinence to absorb urine leakage. This prevents ... wearer from potential embarrassment. The pad ensures that the ...
Breaking Medicine News(10 mins):Health News:Bronchoscopes Industry 2019 Forecasts for Global and China Region in New Research Report at ReportsnReports.com 2Health News:Bronchoscopes Industry 2019 Forecasts for Global and China Region in New Research Report at ReportsnReports.com 3Health News:ASCP Launches Social Media Campaign in Honor of World AIDS Day 2Health News:U.S. Robotic Surgery Market Set to Diversify and Grow: Intuitive Surgical’s ‘da Vinci’ Robot Revenues to Increasingly Rely On Procedures and Services 2Health News:Research Shows Surprising Number of US Workers Affected by Lack of Sleep 2
... 21 Omnicell,Inc. (Nasdaq: OMCL ), a leading ... results for its first quarter ended,March 31, 2008., ... totaled $62.1,million, up $4.1 million or 7.2% from the ... from the first quarter of 2007., First quarter ...
... MDS Board, TORONTO, April 21 /PRNewswire-FirstCall/ - MDS ... and services to the global life,sciences markets, today announced ... William Dempsey, former Executive Vice-President,of Abbott Laboratories, have been ... both Greg and Bill and look forward to benefiting ...
... 6 millimeters in diameter appear more likely to be ... the April issue of Archives of Dermatology, one of ... guidelines currently used by dermatologists to screen for melanoma ... to screen for melanoma, according to background information in ...
... Insurance,Holdings, Inc. ("EIHI") (Nasdaq: EIHI ) today ... (Excellent) financial strength ratings of EIHI members,Eastern Alliance ... Company ("ELH") and upgraded the outlook for EAIG ... specializing in workers,compensation. A.M. Best reaffirmed a stable ...
... also finds survival rates similar, no matter when admission ... to heart attack patients who arrive at hospitals during ... hours tend to receive faster and more comprehensive care, ... affect in-hospital death rates of heart attack patients, said ...
... Successful Transition, BIRMINGHAM, Ala., April 21 ... Hayek has been named president and,chief executive officer ... executive officer, Mike Snow, is resigning his position ... as an advisor on the company,s,board of directors., ...
Cached Medicine News:Health News:Omnicell Announces First Quarter 2008 Results 2Health News:Omnicell Announces First Quarter 2008 Results 3Health News:Omnicell Announces First Quarter 2008 Results 4Health News:Omnicell Announces First Quarter 2008 Results 5Health News:Omnicell Announces First Quarter 2008 Results 6Health News:Omnicell Announces First Quarter 2008 Results 7Health News:Omnicell Announces First Quarter 2008 Results 8Health News:Omnicell Announces First Quarter 2008 Results 9Health News:Omnicell Announces First Quarter 2008 Results 10Health News:Omnicell Announces First Quarter 2008 Results 11Health News:MDS Appoints Two New Directors 2Health News:MDS Appoints Two New Directors 3Health News:Larger skin lesions appear more likely to be melanomas 2Health News:Eastern Alliance Insurance Group and Eastern Life and Health Insurance Company Announce Affirmation of A- (Excellent) A.M. Best Ratings and a Positive Outlook for Eastern Alliance Insurance Group 2Health News:Eastern Alliance Insurance Group and Eastern Life and Health Insurance Company Announce Affirmation of A- (Excellent) A.M. Best Ratings and a Positive Outlook for Eastern Alliance Insurance Group 3Health News:Off-Hours Heart Patients Less Likely to Get Angioplasty 2Health News:SCA Names Andrew Hayek as New President and CEO 2
Used for endobronchial blockade of the left or right lung for procedures which require one-lung ventilation. Supplied sterile in peel-open packages. Intended for one-time use....
... can establish an airway (up to 7.2 mm ... used for fast and safe emergency airway access., ... and a 7.2 mm I.D. airway within seconds. ... ventilation. A suction catheter can be introduced through ...
... Howland lock handle - Chrome-plated brass. Rusch ... standard laryngoscope handles that are compatible with ... standards. The designs of these handles have ... use the world over to minimize maintenance ...
... Standard Chrome plated brass. Available ... a reliable tradition of high quality ... with all standard/conventional blades manufactured to ... these handles have been continually refined ...
Medicine Products: